The introductory document to the Seventh Evaluation Round Questionnaire is essential in the evaluation process. Therefore, it is necessary that the MEM National Coordinating Entity (NCE) of each member state draft and submit the document along with the responses to the Evaluation Questionnaire within set deadlines.

This is an important document so that evaluators can better understand the context and characteristics under which the drug phenomenon develops at the national level. Hence, the Governmental Expert Group (GEG) will have additional information to take into account during their evaluations on the reality of the drug problem in each country and the strategy implemented to address it.

To ensure that the GEG has the most relevant information, suggest that the introductory document be no more than three pages and take into account the following outline:

I. Introduction

The introductory document should include the following elements:

1. General overview of the geographic, economic and social reality of the country and the political - administrative system;
2. Brief history of the drug phenomenon in the country; and
3. Emerging challenges in addressing the problem.

II. National Drug Strategy: General Description1:

Suggest including the following aspects:

1. Description of the national drug plan and/or strategy objectives; and
2. General description on including the gender and human rights perspectives in drug public policies in the country.

1 Also, a list of web pages can be attached to include additional information on the drug plan or strategy of the country.
III. Conclusion

The conclusion should include the following:

1. A general outlook on the country’s implementation of its national drug plan and/or strategy;
2. Specific areas of the drug plan and/or strategy that were prioritized during the 2014 – 2018 period; and
3. Additional information that the country deems relevant to bear in mind and that is not in the responses to the MEM Questionnaire.

---

2 If your country has carried out a results evaluation on the national drug plan and/or strategy, please attach the corresponding document or web link.